avenciguat + esomeprazole

Avenciguat + esomeprazole is a theoretical combination of two oral pharmaceutical agents: avenciguat, a soluble guanylate cyclase (sGC) stimulator in development primarily for fibrotic and cardiopulmonary diseases, and esomeprazole, an approved proton pump inhibitor that reduces gastric acid secretion by inhibiting the H+/K+-ATPase in gastric parietal cells. Avenciguat is under clinical investigation for diseases such as systemic sclerosis and diabetic complications, while esomeprazole is widely used for gastroesophageal reflux disease (GERD), peptic ulcers, and related acid disorders. There are no known clinical developments or approved indications for this combination itself as of the latest available data.